India is preparing to tighten control over pharmaceutical packaging materials.
The government is reportedly planning a registration system for manufacturers and suppliers of printed drug packaging materials. These materials may need registration certificates and unique identification numbers.
At first glance, this sounds like a packaging issue.
It is not.
It is a drug safety issue.
Recent cases involving fake semaglutide and rabies vaccine products have exposed a serious problem: genuine-looking packaging can be misused to make counterfeit medicines appear legitimate.
In pharmaceutical supply chains, packaging is often treated as secondary to APIs and finished drugs.
That view is outdated.
Packaging is part of the medicine’s identity. Labels, cartons, blister foils, inserts, batch details and printed materials help patients, hospitals, distributors and regulators confirm whether a product is real.
If those materials are not controlled, counterfeiters get an easier path into the market.
This is why India’s proposed move matters.
By extending oversight to printed packaging suppliers, regulators are trying to close a gap in the anti-counterfeit chain.
For pharmaceutical companies, the implication is direct: packaging procurement may become more regulated, more documented and more traceable.
Suppliers may need better recordkeeping. Buyers may need to verify source legitimacy more carefully. Audits may become more common.
The impact will not stop at packaging manufacturers.
API suppliers, formulation companies, contract manufacturers, distributors and exporters will all need to pay more attention to documentation around packaging materials.
This is especially important for high-demand or high-value medicines.
Products such as GLP-1 drugs, vaccines, oncology medicines, antibiotics and biologics are attractive targets for counterfeiters because demand is high and margins can be large.
Counterfeit prevention is moving beyond the drug itself and into every visible part of the product.
For international buyers, India’s tighter rules could improve confidence in the long run.
For suppliers, however, it may add compliance work and cost.
Still, the direction is hard to argue with.
A drug is not protected only by what is inside the vial, tablet or capsule.
It is also protected by the supply chain around it.
